Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Assertio Reports Second Quarter 2025 Financial Results
August 11, 2025 4:05 PM EDTSecond Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million
Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy
LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients needs, today reported financial results for the second quarter ended June 30, 2025.
Said Brendan OGrady, Chief Executive Officer, The... More
